Combined Use of the Ab105-2phiDeltaCI Lytic Mutant Phage and Different Antibiotics in Clinical Isolates of Multi-Resistant Acinetobacter baumannii
Blasco Otero, Lucía; Ambroa Abalo, Antón; Lopez, Maria; Fernández García, Laura; Bleriot Rial, Ines Maria; TRASTOY PENA, ROCIO; Ramos-Vivas, Jose; Coenye, Tom; Fernandez-Cuenca, Felipe; Vila, Jordi; Martinez-Martinez, Luis; Rodriguez-Bano, Jesus; Pascual, Alvaro; Cisneros, Jose Miguel; Pachon, Jeronimo; Bou Arévalo, Germán; Tomás Carmona, María del Mar
![Thumbnail](/xmlui/themes/Mirage2//images/thumbnails/thumn_cientif.png)
Identificadores![](/xmlui/themes/Mirage2//images/despl_identif.png)
Identificadores
Visualización o descarga de ficheros![](/xmlui/themes/Mirage2//images/despl_contenidos.png)
Visualización o descarga de ficheros
Fecha de publicación
2019Título de revista
MICROORGANISMS
Tipo de contenido
Artigo
DeCS
Acinetobacter baumanniiMeSH
Acinetobacter baumanniiResumen
Phage therapy is an abandoned antimicrobial therapy that has been resumed in recent years. In this study, we mutated a lysogenic phage from Acinetobacter baumannii into a lytic phage (Ab105-2phiDeltaCI) that displayed antimicrobial activity against A. baumannii clinical strain Ab177_GEIH-2000 (isolated in the GEIH-REIPI Spanish Multicenter A. baumannii Study II 2000/2010, Umbrella Genbank Bioproject PRJNA422585, and for which meropenem and imipenem MICs of respectively, 32 microg/mL, and 16 microg/mL were obtained). We observed an in vitro synergistic antimicrobial effect (reduction of 4 log-7 log CFU/mL) between meropenem and the lytic phage in all combinations analyzed (Ab105-2phiDeltaCI mutant at 0.1, 1 and 10 MOI and meropenem at 1/4 and 1/8 MIC). Moreover, bacterial growth was reduced by 8 log CFU/mL for the combination of imipenem at 1/4 MIC plus lytic phage (Ab105-2phiDeltaCI mutant) and by 4 log CFU/mL for the combination of imipenem at 1/8 MIC plus lytic phage (Ab105-2phiDeltaCI mutant) at both MOI 1 and 10. These results were confirmed in an in vivo model (G. mellonella), and the combination of imipenem and mutant Ab105-2phiDeltaCI was most effective (p < 0.05). This approach could help to reduce the emergence of phage resistant bacteria and restore sensitivity to antibiotics used to combat multi-resistant strains of Acinetobacter baumannii.
![](/xmlui/themes/Mirage2//images/final_lines.png)